Compare AGEN & HIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGEN | HIX |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.6M | 351.3M |
| IPO Year | 1999 | 1998 |
| Metric | AGEN | HIX |
|---|---|---|
| Price | $6.84 | $3.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $26.33 | N/A |
| AVG Volume (30 Days) | ★ 856.6K | 358.6K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $42,877,086.00 | N/A |
| Revenue This Year | $9.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.35 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $2.71 | $3.34 |
| 52 Week High | $10.19 | $4.33 |
| Indicator | AGEN | HIX |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 47.01 |
| Support Level | $6.66 | $3.46 |
| Resistance Level | $8.64 | $4.04 |
| Average True Range (ATR) | 0.46 | 0.05 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 57.46 | 88.24 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its primary investment objective is to maximize current income by investing at least 80% of its net assets, plus any borrowings for investment purposes, in high-yield debt securities. As a secondary objective, the Fund seeks capital appreciation to the extent consistent with its objective of seeking to maximize current income.